A stratified randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER
Latest Information Update: 08 Nov 2023
At a glance
- Drugs Atomoxetine (Primary) ; Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms SNAPPER
Most Recent Events
- 25 May 2022 New trial record
- 18 May 2022 Full patient recruitment is expected to be completed by 28 Feb 2025, according to ISRCTN: Current Controlled Trial record.